IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System

NCT ID: NCT03700372

Last Updated: 2021-10-14

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-13
• Study Completion Date: 2021-03-03

Brief Summary

IMPACT is a prospective, single-arm, multi-center, safety and feasibility study evaluating the IOWA Approach Cardiac Ablation System (FARAPULSE, Inc.) for the treatment of paroxysmal atrial fibrillation.

Detailed Description

Patients with paroxysmal atrial fibrillation scheduled to undergo cardiac surgery will be screened for enrollment per protocol inclusion and exclusion criteria. Enrolled patients will then undergo ablation using the IOWA Approach Cardiac Ablation System (FARAPULSE, Inc.), followed by concomitant cardiac surgery. Subjects will be followed at 7 days, 30 days, 3 months, 6 months and 12 months with a blanking period for recurrent atrial fibrillation or atrial tachycardia of 3 months following the index ablation procedure.

Conditions

Paroxysmal Atrial Fibrillation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IOWA Approach Cardiac Ablation

Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.

Group Type: EXPERIMENTAL

IOWA Approach Cardiac Ablation System

Intervention Type: DEVICE

Epicardial ablation using the IOWA Approach Cardiac Ablation System

Interventions

IOWA Approach Cardiac Ablation System

Epicardial ablation using the IOWA Approach Cardiac Ablation System

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Patients who are ≥ 18 and ≤ 70 years of age on the day of enrollment.

2. Diagnosis of paroxysmal atrial fibrillation defined as symptomatic paroxysmal AF with at least two episodes of paroxysmal AF observed within the 12 months preceding inclusion.

3. Patients are resistant to anti-arrhythmic treatments.

4. Anteroposterior Left atrial diameter ≤ 5.5 cm as documented by transthoracic echocardiography (TTE) or computed tomography (CT) within 3 months prior to the procedure.

5. Subject has no contraindications to intraoperative transesophageal echocardiography;

6. Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) to be performed including open-heart surgery for one or more of the following:

• Mitral valve repair or replacement,
• Aortic valve repair or replacement
• Tricuspid valve repair or replacement, or
• Coronary artery bypass procedures

7. Left ventricular ejection fraction ≥40% as documented by TTE within 12 months prior to the procedure.

8. Received a standard cardiac work up and is an appropriate candidate for an investigational procedure as determined by trial investigators.

9. Subject is willing and capable of providing Informed Consent to undergo study procedures and participate in all examinations and follow-ups associated with this clinical trial.

Exclusion Criteria

1. Abnormal cardiac and/or epicardial anatomy (such as adhesion, anomalous coronaries, thickened epicardium, etc.) or pericardial reflections on TTE, MRI or CT.

2. Prior left-sided cardiac ablation.

3. Prior history of open chest surgery and/or any procedure where the pericardial space was entered or instrumented (pericardiocentesis, catheter mapping and /or ablation).

4. Patient has a prosthetic heart valve.

5. Patient has a left atrial appendage device

6. Prior history of pericarditis or pericarditis within 3 months based on the TTE examination.

7. Subject is a woman of child bearing age

8. Prior history of rheumatic fever.

9. Prior history of medical procedure involving instrumentation of the left atrium (previous ablation, Atrial septal defect) ASD closure, left atrial appendage occlusion)

10. History of severe chronic gastrointenstinal problems involving the esophagus, stomach and/or untreated acid reflux

11. History of abnormal bleeding and/or clotting disorder.

12. Active malignancy or history of treated cancer within 24 months of enrollment.

13. Clinically significant infection or sepsis.

14. History of stroke or TIA within prior 6 months

15. New York heart Association (NYHA) class IIIb or IV congestive heart failure and/or any heart failure hospitalization within 3 months prior to enrollment.

16. Body mass index > 35.

17. Estimate glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or has ever received dialysis.

18. History of untreated and serious hypotension, bradycardia or chronotropic incompetence.

19. Any of the following within 3 months of enrollment:

• Major surgery except for the index procedure
• Myocardial infarction
• Unstable angina
• Percutaneous coronary intervention (e.g., CABG or PTCA)
• Sudden cardiac death event
• Left atrial thrombus that has not resolved as shown by TEE (transesophageal echo) or CT
• Implant of pacemaker, ICD (implantable cardioverter defribillator) or CRT (cardiac resynchronization therapy).

20. Solid organ or hematologic transplant, or currently being evaluated for an organ transplant

21. History of pulmonary hypertension with Pulmonary systolic artery pressure >50 mm Hg, severe Chronic Obstructive Pulmonary Disease or restrictive lung disease.

22. Patients with any other significant uncontrolled or unstable medical condition (such as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or significant coagulation disorder).

23. Life expectancy less than one year.

24. Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.

25. Enrolled in another cardiac clinical trial that would interfere with this trial.

26. Life expectancy less than one year.

27. Clinically significant psychological condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.

28. Enrolled in another cardiac clinical trial that would interfere with this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston Scientific Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU Bordeaux

Pessac, , France

Countries

France

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan: CS0172-001

View Document

Document Type: Study Protocol and Statistical Analysis Plan: CS0172-002

View Document

Other Identifiers

CS0172

Identifier Type: -

Identifier Source: org_study_id